Related by context. All words. (Click for frequent words.) 72 dilutive effect 65 dilution 65 dilutive securities 63 dilutionary 61 antidilutive 57 accretive 55 Dilutive 53 modestly dilutive 52 EPS accretive 51 convertible debenture 50 mildly dilutive 50 convertible subordinated 50 fully diluted 49 unvested 49 convertible debentures 49 modestly accretive 49 exchangeable notes 49 convertible preferred 48 earnings pershare 48 Dilution 48 VaxGen stockholders 48 unvested options 48 contingently convertible debt 48 adopting SFAS #R 48 unvested restricted 48 Contingent Value Rights 48 Share repurchases 48 mandatorily convertible preferred 48 minimally dilutive 48 contingently convertible 48 dilutionary effect 48 pro rata renounceable 47 diluted EPS 47 nondividend distribution 47 GAAP EPS 47 issuable 47 Avigen stockholders 47 diluted 47 accretive thereafter 47 convertible redeemable preferred 47 convertible notes 47 4/share 47 FSP EITF #-#-# [002] 47 convertible redeemable 47 contingently convertible securities 47 #.#/share [002] 47 normalized EPS 46 SEK #,#,#,# 46 share repurchases 46 Neurogen stockholders 46 convertible bonds 46 underwriters overallotment option 46 repurchases 46 shares issuable upon 46 Filtran Microcircuits Inc. 46 mildly accretive 46 pro forma 46 convertible promissory notes 46 Ception 46 OTTI charges 46 unvested restricted stock 46 convertible perpetual 46 Symphony GenIsis 45 exercisable 45 equity raisings 45 Pro forma net 45 exerciseable 45 mandatorily redeemable convertible 45 non renounceable 45 MSR hedging 45 shares issuable pursuant 45 accept oversubscriptions 45 NOL utilization 45 convertible debentures NCDs 45 noncash impairments 45 acquiror 45 SFAS #R 45 Statement #R 45 meaningfully accretive 45 antidilution 45 contingently issuable shares 45 recapitalization 45 overcapitalized 45 Unvested 45 non recurring 45 - Diluted 45 commonstock 44 cumulative perpetual 44 renounceable 44 Contingent Value Right 44 significantly undervalues NRG 44 Facet Biotech stockholders 44 Projected FFO 44 3/share 44 EPS accretion 44 exercisability 44 nonconvertible preferred 44 accelerated vesting 44 nonrecurring expenses 44 Pre QT Financing 44 QT Financing 44 Convertible Subordinated Debt 44 FAS #R 44 issuable pursuant 44 Cortelco 44 5/share 44 Convertible Debt 44 Appreciation Rights 44 convertible exchangeable 44 redeemable preferred 44 Arana Therapeutics Limited 44 underwritten dividend reinvestment 44 shares issuable 44 opportunistically repurchase 44 netincome 44 issuances 44 convertible debenture financing 44 Miikana Therapeutics 44 CDO writedowns 44 Resulting Issuer Shares 44 EITF #-# [001] 44 stockholder approval 44 mandatorily convertible 43 Express Scripts Caremark 43 Deerfield Triarc 43 Montaur 43 fully subscribed 43 unsecured redeemable 43 BEE transaction 43 brokered Private Placement 43 redeemable preferred stock 43 Laurus Funds 43 Oxy ER 43 RTO Financing 43 expensed 43 MA PFFS 43 Overallotment Option 43 option expensing 43 Evercore LP 43 Million Convertible Debenture 43 balance sheet 43 restatement 43 MuniPreferred 43 compensation expense 43 greenshoe 43 Adjusted diluted 43 Private Placement Offering 43 Preferred Stock 43 Convertible Preferred Stock 43 unsecured debentures 43 pref shares 43 Teva Yanai 43 acquirors 43 overallotment provision 43 B Preferred Stock 43 ACLARA 43 accretively 43 amortization expense 43 impair Lillian Vernon 43 Cyries 43 dilutive issuances 43 Cash Consideration 43 Convertible Notes 43 convertible promissory note 43 Atrium Biotechnologies 43 underwriting discounts commissions 43 Repurchasing 43 private placement 43 Pro forma Adjusted EBITDA 43 subordinated convertible bonds 43 Contingent Convertible Senior 43 MagPotash 43 LIFO accounting 43 DAC unlock 43 danoprevir 43 Flow Through 43 imputed dividend 43 repurchase 42 #.#ca share [002] 42 depreciation amortization depletion 42 Assumed exercise 42 callable 42 DCF valuation 42 Net Tangible Assets 42 FCCB 42 FFO allocable 42 No. #R SFAS 42 Primelead 42 CreXus 42 repurchased 42 loss carryovers 42 Pro forma diluted 42 vest ratably 42 #,#,# warrants exercisable 42 convertible subordinated notes 42 SFAS No.#R 42 Institutional Placement 42 Rights Offering 42 expensing 42 Greenshoe option 42 Bought Deal Offering 42 buybacks 42 CAD#m [002] 42 franked dividend 42 n#.# [002] 42 equity 42 Pro forma EPS 42 amortization 42 Pro forma adjustments 42 Diluted FFO 42 ATCF 42 RSUs 42 OFCD Optionally Fully 42 noncumulative perpetual preferred 42 Overallotment 42 - Adjusted [022] 42 preferential allotments 42 TruPS 42 earnout 42 TRUPs 42 debentures 42 unconsolidated investee 42 asset monetizations 42 stock basedcompensation 42 pro forma EPS 42 Senior Exchangeable Notes 42 en actions ordinaires 42 FASB #R 42 leveraged recapitalization 42 pershare 42 Metabasis stockholders 42 unrealized derivative gains 42 Convertible Loan 42 #,#,#,# equity shares [001] 42 undercollateralized 42 Paivis 42 convertible redeemable preference 42 AXA APH minority 42 unitholder distributions 42 fully underwritten renounceable 42 Unlisted Options 42 Repurchased 42 acquirer 42 voluntary prepayment 42 renounceable entitlement offer 42 DKK #,#,# 42 Debenture Units 42 requisite regulatory approvals 42 PanAndean 42 diluted weighted 42 FFO 42 non forfeitable dividends 42 cash flows 42 Tenovis 42 Fortsum 42 marginally accretive 42 compulsorily convertible debentures 42 DSL.net s 42 Subscription Receipt Offering 42 NPRFC 42 non forfeitable 42 TARP repayment 42 AFFO payout ratio 42 PRRF 42 undrawn revolver 42 CoCo bonds 42 freely tradable 41 indebtedness incurred 41 fully underwritten 41 Recapitalisation 41 PDTI 41 #.#/sh 41 Crocotta 41 redeemable preference shares 41 buyback authorization 41 Loss Per Common Share 41 immediately accretive 41 Merged Entity 41 dis synergies 41 unsecured subordinated debentures 41 LGP Allgon 41 mandatorily redeemable 41 Flow Through Financing 41 Shares issuable pursuant 41 renounceable rights 41 Purchase Warrant 41 Senior Unsecured Debentures 41 Conditional Placement 41 1/share 41 Fully diluted earnings 41 FSAH 41 Mandatory Convertible Notes 41 = Weighted average [003] 41 receive nonforfeitable dividends 41 Merger Transaction 41 Xantic acquisition 41 normalized FFO 41 Citadel SMaRT 41 accelerated renounceable entitlement 41 Existing Warrants 41 trust preferreds 41 Silvercorp Offer 41 covenant breaches 41 First Tranche 41 fully franked dividends 41 Senior Secured Debentures 41 debenture 41 nondeductible expenses 41 issuable upon conversion 41 Convertible Preferred Shares 41 On2 stockholders 41 EPADS estimate 41 X Ceptor 41 diluted share 41 Shares issuable 41 equity financings 41 Omnibus Incentive Plan 41 pro forma EBITDA 41 CoCos 41 overcapitalised 41 Qualified Institutional Buyers QIB 41 LTM Adjusted EBITDA 41 perpetual preferred 41 Seriatim 41 MDS Proteomics 41 subordinated debentures 41 convertible debentures NCD 41 #.#x #E [001] 41 compulsorily convertible 41 Accelerated vesting 41 CVRs 41 EPE unitholders 41 EBITDAO 41 senior subordinated convertible 41 overallotment options 41 exchangeable bonds 41 divesting noncore assets 41 unsecured convertible 41 mandatorily convertible notes 41 undistributed earnings 41 inventories revalued 41 Financings 41 AuthenTec stockholders 41 flowthrough 41 Refinancing Transactions 41 Normalized EPS 41 Martison Project 41 MFB Corp 41 Freewest shareholders 41 unbooked resource potential 41 issuable upon exercise 41 TCE ratio 41 marketable securities 41 Substantial Issuer Bid 41 OTTI write downs 41 cash fl ows 41 Over Allotment 41 Huarun minority interest 41 debt extinguishments 41 Agennix Incorporated 41 Debenture Financing 41 Merger Proposal 41 Debt Conversion 41 Preference Share 41 GDR FCCB 41 TOBs 41 Flow Through Offering 41 Non GAAP diluted 41 Fancamp Announces 41 Non Renounceable Rights 41 Fully diluted 41 Scheme Consideration 41 underwriters overallotment 41 units NFT Units 41 EUR #,#,#.# [002] 41 units RSUs 41 aP S 41 Chesstown 41 AVONEX multiple sclerosis 41 Adjusted EBITDA excludes 41 Positively impacting 41 OPANA franchise 41 Common Share Purchase 41 Service1st 41 Conversion Price 41 restatements 41 EDITDA 41 items affecting comparability 41 adopting poison pill 41 #.#ca share [003] 40 Amalco Shares 40 convertible 40 Fairquest 40 Upfront Payment 40 de levering 40 goodwill impairment charge 40 Normalized FFO 40 B Convertible Preferred 40 Q2 adj 40 C Convertible Preferred 40 GDR ADR 40 Contingent Convertible Senior Subordinated 40 Rhein Biotech NV 40 unamortized financing 40 Jupiters JUP 40 = LMusic Store iTMS 40 FCCB GDR 40 placees 40 Incremental weighted 40 HSR clearance 40 Convertible Bond 40 applicable xxi 40 levered balance sheet 40 Annual Incentive Plan 40 Diluted AFFO 40 Noront Offer 40 unvested stock 40 2/share 40 OCEANE bonds 40 Proposed Financing 40 secured debenture 40 Zeehan Zinc 40 Variable Interest Entity 40 #,#,# Ordinary Shares [001] 40 unexercised options 40 Pro forma 40 repurchasing 40 accretion 40 worth #mln rub 40 promissory notes payable 40 - Non GAAP [015] 40 reissuances 40 renounceable pro rata 40 Proposed Takeover 40 adopted SFAS #R 40 No. #R 40 detachable warrants 40 = quarterback Spergon Wynn 40 Non Brokered Offering 40 materially undervalues 40 earnouts 40 earnout payments 40 share repurchase authorizations 40 Dilutive securities 40 OTTI charge 40 Common Share 40 Nasdaq KOSP 40 #,#,# Flow Through 40 #/shr 40 Cashless exercise 40 Option Schemes 40 Second Tranche 40 Corporate HiMEDS Units 40 deductible goodwill impairment 40 FFO FFO 40 Secured Convertible Debentures 40 FCCBs 40 Stapled Unit 40 Grandfathered Person 40 exchangeable shares 40 Montec Holdings 40 marketable securities totaled 40 EdgeStone 40 E cumulative redeemable 40 Medco repurchased 40 HiMEDS Units 40 BNP Exane Paribas 40 redeemable convertible preferred 40 CPIF 40 secured convertible debenture 40 uncollectible accounts receivable 40 Convertible preferred 40 convertible subordinated debentures 40 expire unexercised 40 share repurchase authorization 40 TRUPS 40 amalgamated corporation 40 FAS# R 40 Evotec Neurosciences 40 AFFO 40 CapGen Offering 40 CAD#.# [004] 40 b Represents 40 INOVA Geophysical 40 Illumigen 40 refinance indebtedness 40 warrant Warrant exercisable 40 subordinate voting 40 Goldking 40 dividend reinvestment plan 40 Common Stock 40 unexercised 40 QIP route 40 optionholders 40 GDRs ADRs FCCBs 40 cocos 40 ARYZTA 40 pro rata entitlement 40 Lundin Transaction 40 Lundin Inmet 40 -APRIL #TH DAY 40 noncumulative 40 delevering 40 Fully diluted weighted 40 analyst Maarten Altena 40 -Amos Harel Haaretz Correspondent 40 #p/share [002] 40 unsecured convertible promissory 40 purchase warrants exercisable 40 BVPS 40 upsize option 40 acquiree 40 Recapitalization 40 convertible debenture NCD 40 ARPs 40 Shares issuable upon 40 AUD#.# [005] 40 Stapled Units 40 per dilutedshare 40 Flow Through Private Placement 40 unitholder approval 40 Hanlong transaction 40 shareholders 40 dilute 40 theacquisition 40 NYSE CXS 40 adjusted distributable cash 40 LitFunding 40 secured convertible debentures 40 junior subordinated debentures 40 exclude noncash 40 repriced 40 FFOM 40 liquidation preference 40 Convertible Debentures 40 TruOFFICE subscribers 40 cumulative redeemable convertible 40 Offeror intends 40 transaction 40 GoldTrust 40 TSARs 40 intangible assets impairment 40 cashcall 40 Authorized #,#,# shares 40 Derivative Liabilities 40 Preferred Stockholders 40 Mohan Maheswaran owns 40 Common Shares 40 #c/share [002] 40 realizable value 40 delevered 40 warrants expired unexercised 40 Subordinate Note 40 - Adjusted [028] 40 NPVs 40 pretax goodwill impairment 40 unaccreted discount 40 cornered amalgamation 40 ÁKK 40 CanSub 40 ARIF II 40 nonvested shares 40 Entitlement Issue 40 = Diluted [014] 40 #.#/ADR 40 Carrier ARW 40 pro forma basis 40 Core FFO 40 remaining untendered 40 PIPE Financing 40 Deemed dividend 40 FIRB approval 40 Matt Spick 40 putable 40 LTIPs 40 Purchased intangibles 40 Pala Partial Offer 40 intangibles amortization 39 warrants exercisable 39 Finder Units 39 Finder Option 39 Secured Convertible Notes 39 FCCBs aggregating 39 Sunov 39 Willowstar 39 asset disposals 39 #.#p #.#p [008] 39 #E EPS 39 optionally convertible 39 Financing Activities Issuance 39 KoriTambo 39 Mandatorily Exchangeable Notes 39 CompAir acquisition 39 NFT Unit 39 broker warrants exercisable 39 AutoZone repurchased 39 cumulative redeemable 39 Pharmagesic 39 Brokered Placement 39 FCCBs GDRs ADRs 39 Senior Secured Convertible Notes 39 Caliper microfluidics 39 Rights Plan 39 EITF #-# [002] 39 From Operations AFFO 39 Citadel HYTES 39 Frontino Acquisition 39 proforma EPS 39 #,#,# ADSs [001] 39 SIDEX 39 B redeemable convertible 39 Preferential Allotment 39 stockholders 39 convertible debentures Debentures 39 SEK #,#,#.# 39 - BaImprint Newspapers 39 subscription receipts 39 ASC #-# 39 Reorganization Proposal 39 Axiologix 39 Non GAAP Diluted EPS 39 Cumulative Perpetual Preferred Stock 39 Convertible Preferred 39 ReAble 39 Shellbridge 39 Spac 39 consolidated OIBDA 39 Notes LYONs 39 Revised Proposal 39 normalized EBIT 39 divestures 39 Each Subscription Receipt 39 uncertainties materialize Shire plc 39 deducting underwriting 39 Amalgamation Amalco 39 CEFF 39 Fully diluted EPS 39 accretable yield 39 dacetuzumab collaboration 39 Inc MYL MYL 39 Pari passu 39 intangible impairments 39 Combination Agreement 39 = DilutedG. Neeleman 39 deleveraged balance sheet 39 BRL#.#bn [002] 39 discounted cashflow 39 Mowood LLC 39 Canext 39 Ordinary Share 39 recapitalizes 39 share buybacks 39 notifiable transaction 39 Subordinated LP 39 Aurvista 39 Remedium 39 NASDAQ SAMAS 39 mandatorily convert 39 6/share 39 Vaccinex 39 Core Tier 39 operatingincome 39 Matthias Heck 39 Stock Incentive Plan 39 securityholder approval 39 PennFed 39 RedWater 39 MZT Holdings 39 Convertible Debenture 39 underwriter overallotment option 39 repricings 39 Authorized #,#,# [002] 39 Incentive Compensation Plan 39 carryforwards 39 Equinix excludes 39 senior unsecured debentures 39 worth #.#mln rub 39 Option Plan 39 Adjusted Earnings 39 Priority Equity 39 Debenture 39 Fixed Rate Non Cumulative 39 Friendly LRL 39 Comparable FFO 39 NNL preferred shareholders 39 Assumed conversion 39 Senior Convertible Notes 39 nausea superficial edema 39 nonrecourse 39 TC PipeLines 39 Adjusted EPS 39 franking credits 39 Antler Creek Shares 39 - - Diluted [008] 39 SHARE OPTIONS 39 equityholders 39 Business Combination 39 gross proceeds 39 Qualified Institutions 39 #x FY# EPS 39 #c/share [001] 39 Revance 39 EPS 39 Tranche 39 #.#p #.#p [007] 39 divestitures 39 disinterested shareholder 39 nonoperating items 39 ABL Revolver 39 #,#,# FT Units 39 Surface Specialties acquisition 39 SEBI ICDR Regulations 39 SIPAR 39 TSX VENTURE CXZ 39 Hyprop unitholders 39 Onex Entities 39 TSX VENTURE SYI 39 Xtract owns 39 macro headwinds 39 ESML Intressenter 39 non gaap 39 QSBS 39 Hudbay 39 Stapled Securities 39 Newell Rubbermaid Declares Dividend 39 Distributions declared 39 Symphony ViDA 39 Non GAAP EPS 39 allotment option 39 Tendered Notes 39 Related Parties 39 AOLS Holdings 39 distributable reserves 39 #.#x FY# [002] 39 traunch 39 prorata 39 moire sleeveless trench coat 39 CAD#.# [006] 39 Borrowing Fees 39 FT Units subscribed 39 Recapitalization Agreement 39 CY# EPS 39 Modified EBITDA 39 NFT Units 39 standardized distributable cash 39 SMTEK 39 Mike Trippitt 39 issuable upon 39 Biomerge 39 adjusted EPS 39 USD#.# [001] 39 refranchising 39 Separate Subordinated Notes 39 income allocable 39 PERLS V 39 Warrant Exercise 39 Amends Terms 39 TSX BTE.UN 39 Kalpesh Kapadia 39 AUD#.# [001] 39 Barrier Warrants 39 SFSB Inc. 39 DTR #.#.#R 39 Cleartel 39 analyst Albert Savastano 39 ANS Parties 39 buyback 39 goodwill impairment 39 Kereco 39 MFG Ordinary Shares 39 Mario Mendonca 39 Mexgold 39 Financing Transactions 39 Ebita margin 39 Neurobionix 39 Merger Consideration 39 Non Dilutive 39 aftertax 39 NOL carryforwards 39 Limited ASX DGR 39 CAD# [002] 39 Bonus Warrants 39 depreciation accretion 39 oversubscriptions 39 unsecured debenture 39 US#.#bn [002] 39 FCCB conversion 39 Convertible Preferred Units 39 Proposed Transactions 39 DiaMed acquisition 39 Luuk van Beek 39 EdgeStone Funds 39 Terminate Merger Agreement 39 LIFO provision 39 undiluted basis 39 FT Unit 39 Bought Deal Financing 39 pro rata portion 39 Non Convertible Debentures 39 Zareba shareholders 39 payout ratio 39 applicable xv 39 proceeds therefrom 39 receivable securitization 39 Preferred Units 39 deducting underwriting commissions 39 infrequently occurring 39 Repurchase Program 39 repurchase authorizations 39 Alain Tchibozo 39 unamortized issuance costs 39 Including unvested 39 EPADS estimates 39 golden parachute arrangements 39 optionally convertible preference 39 #x PER 39 Canaccord Relief Program 39 Zero Coupon Convertible Debentures 39 RSU Plan 39 Daniel Fannon 39 Restricted Share 39 Private Placement Financing 39 ArPetrol Transaction 39 Verint Systems Inc 39 Share Consideration 39 Aumento 39 Aeroflex stockholders 39 aggregate liquidation preference 39 worth #.#bn rub [001] 39 BIOCEUTICALS 39 #.#cps [002] 39 Windrace 39 ABCP holdings 39 deleverages 39 Amended Merger Agreement 39 analyst Darko Mihelic 39 Non FT Units 39 ofapproximately 39 Facet stockholders 39 NKr 39 ATS Andlauer 39 Initial Purchasers 39 cumulative redeemable preference 39 FDIC indemnification 39 Greenshoe Option 39 FSP APB #-# 39 prorations 39 convertible CoCo 39 Mike Trippitt analyst 38 significantly undervalue 38 addback 38 Flow Through Common Share 38 Neosil 38 demergers 38 #.#/share [004] 38 undemanding valuation 38 unamortized debt 38 incremental 38 = Basic [021] 38 diluting 38 Cornerstone BioPharma Holdings 38 #,#,# #,#,# SHAREHOLDERS EQUITY [001] 38 Medigen 38 ZCI Offer 38 convertible unsecured debentures 38 Fourth Supplemental Indenture 38 OCEANE convertible bonds 38 CAD#.# [005] 38 Convertible Tranche 38 shares DISCRETIONARY MANAGED 38 thetransaction 38 - Adjusted [031] 38 OFCDs 38 Senior Secured Convertible 38 wholly unconditional 38 thecompletion 38 Shareholder Claims 38 Solectron pro forma 38 Sunesis Pharmaceuticals 38 Graniz 38 Junior Subordinated Debt 38 NFT Warrant 38 Karusel hypermarket chain 38 Value Creation Plan 38 identifiable intangibles 38 nonrecurring 38 Pamrapo Bancorp 38 Guidant vascular 38 noncash 38 Common Share Offering 38 Stockholder Rights Plan 38 tendering holders 38 Noncash 38 Valentis 38 cash flow 38 unsecured convertible debentures 38 supplemental indentures effecting 38 Diluted earnings 38 CC Finco 38 subordinated unsecured 38 Fording Teck 38 Antler Creek 38 Mineralfields Group 38 Contingent consideration 38 Redeemable Share 38 Redeemable Preferred Shares 38 nonconvertible debt 38 Alkermes plc 38 OneEx 38 warrant exercisable 38 Inergy Holdings 38 subordinated debt 38 Floating Contracts 38 accreted value 38 Divestments 38 Granahan McCourt 38 Bought Deal 38 USPoly 38 NeuroMedix 38 CF Industries stockholders 38 BPSAG 38 revolver borrowings 38 LSRI Holdings 38 releveraging 38 Unearned compensation restricted 38 Capital Reorganisation 38 Xylodyne 38 AcadeMedia 38 = LIABILITIES AND SHAREHOLDETrevor Arran 38 AOCL 38 attractively priced 38 Senior Subordinated Convertible Notes 38 GBPO 38 Non GAAP net 38 Fording unitholders 38 USD5m 38 railcar deliveries 38 loss NOL carryforward 38 Airgas stockholders 38 Orbitech 38 EUR -#.# [001] 38 Offer Amount 38 Lundin TSX LUN 38 Praecis 38 Copano commodity 38 Bicifadine 38 Cellpep 38 Michael Taiano 38 OcuSense 38 Mr. Mihaylo 38 Brokered Financing 38 oversubscribed 38 intercompany loans 38 #.#/shr [002] 38 Plazacorp announces 38 Annidis 38 OTCBB GYPH 38 necessary regulatory approvals 38 LTIP 38 Trups 38 No. #R Share 38 unamortized deferred 38 Panitumumab 38 loss carryforwards 38 Facet Biotech Corporation 38 triphendiol 38 BUY Rating 38 Proposed Transaction 38 aftertax gain 38 c Relates 38 Greenshoe 38 Caroline Loewy 38 Offerors Commercial applies 38 Preferred Shares 38 Regeneron Pharma 38 Redeemable Preferred 38 Million Flow Through 38 Distribution FAD 38 Payment FAS #R 38 RAPTIVA R 38 - Balance [003] 38 retrospectively adjusted 38 OTPPB 38 repricing 38 mandatorily redeemable preferred 38 Closes Flow Through 38 mandatory redeemable preferred 38 Units RSUs 38 Vertex Pharma 38 consents authorizations 38 Long Term Incentive Plan 38 Canshale 38 Proposed Arrangement 38 irrevocable acceptances 38 = Average [001] 38 CHLP 38 #,#,# #,#,# Contributed surplus [001] 38 Dividend Payout 38 vesting provisions